Articles with public access mandates - Li DingLearn more
Available somewhere: 5
Intracellular Mechanistic Understanding of 2D MoS2 Nanosheets for Anti-Exocytosis-Enhanced Synergistic Cancer Therapy
X Zhu, X Ji, N Kong, Y Chen, M Mahmoudi, X Xu, L Ding, W Tao, T Cai, ...
ACS nano 12 (3), 2922-2938, 2018
Mandates: US National Institutes of Health, National Natural Science Foundation of China
Topical use of quercetin-loaded chitosan nanoparticles against ultraviolet B radiation
W Nan, L Ding, H Chen, FU Khan, L Yu, X Sui, X Shi
Frontiers in pharmacology 9, 826, 2018
Mandates: National Natural Science Foundation of China
Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae
AD Brunaugh, H Seo, Z Warnken, L Ding, SH Seo, HDC Smyth
PloS one 16 (2), e0246803, 2021
Mandates: US National Institutes of Health
Comprehensive insights into intracellular fate of WS2 nanosheets for enhanced photothermal therapeutic outcomes via exocytosis inhibition
N Kong, L Ding, X Zeng, J Wang, W Li, S Shi, ST Gan, X Zhu, W Tao, X Ji
Nanophotonics 8 (12), 2331-2346, 2019
Mandates: National Natural Science Foundation of China
Identification of stability constraints in the particle engineering of an inhaled monoclonal antibody dried powder
AD Brunaugh, L Ding, T Wu, M Schneider, R Khalaf, HDC Smyth
Journal of Pharmaceutical Sciences 111 (2), 403-416, 2022
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program